Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
The new facility marks Align’s first manufacturing presence in India and its fourth globally
The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Subscribe To Our Newsletter & Stay Updated
